India, Dec. 19 -- Pfizer India and Cipla Ltd on Friday announced an exclusive partnership under which Cipla will market and distribute select Pfizer brands in India, significantly enhancing their availability for patients nationwide.
Under the agreement, Cipla will have the exclusive rights to market, distribute and sell Pfizer's cough syrups Corex DX and Corex LS, NSAID Dolonex, proton pump inhibitor Neksium, and oral antibiotic Dalacin C in India. Pfizer will continue to manufacture, source and supply these medicines to Cipla for the Indian market.
Meenakshi Nevatia, Country President, Pfizer India, said the partnership aligns with Pfizer's focus on expanding patient access to its medicines, leveraging Cipla's extensive distribution rea...